Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and ...

The pharmaceutical industry is not stopping there. There are already 100 new drug candidates in trials, all vying for a slice ...

Eli Lilly (LLY), the maker of the blockbuster weight-loss drug ... decision to remove semaglutide — the active ingredient in ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...

Novo Nordisk says many Australians would be willing to pay the out-of-pocket costs for its blockbuster medicines, which can ...

Eli Lilly is now offering four doses of Zepbound in self-administration vials. The lower-cost self-pay option targets people ...